QTc INTERVAL DURATION CLASS AND DRUG THERAPY OF PATIENCE IN A FIRST YEAR AFTER PACEMAKER IMPLANTATION

Keywords: pacemaker, drug therapy, QTc interval duration

Abstract

49 patients (28 female, 21 male) with implanted DDD/DDDR, VVI/VVIR and CRT pacemakers are investigated. Purpose frequency and dose rate of anticoagulants, antiplatelet agents, direct thrombin inhibitors, cardiac glycosides, amiodarone; ivabradine, diuretics, aldosterone antagonists, beta-adrenergic blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), statins were evaluated before, in acute postoperative period (3–5 days), 6 months and 1 year after pacemaker implantation. Patients were divided into classes 1 (normal QTc (320–440 ms)) – 24 (49 %) patients) and 2 (long QTc (> 440 msec)) – 25 (51 %) patients) of QTc interval duration. To process the data using standard statistical procedures using Microsoft Excel. It was more often prescriptions of new anticoagulants, beta-adrenergic blockers, ARBs, statins to patients in the first year after pacemaker implantation. QTc interval duration lengthening was associated with a greater purpose frequency and doses of amiodarone, diuretics, beta-adrenergic blockers, ACE inhibitors, ARBs and statins. Patients with implanted pacemaker need individualized drug therapy according to QTc interval duration, in particular, enhancing antiischemic, antihypertensive, antiarrhythmic therapy and therapy of chronic heart failure in patients with QTc interval duration lengthening.

Downloads

Download data is not yet available.

Author Biographies

M. S. Brynza, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 
M. I. Yabluchansky, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 

References

2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society // Circulation. – 2013. – № 127. – P. e283–e352.

Vserossiyskoye nauchnoye obshchestvo spetsialistov po klinicheskoy elektrofiziologii, aritmologii i kardiostimulyatsii (VNOA). Klinicheskiye rekomendatsii po provedeniyu elektrofiziologicheskikh issledovaniy, kateternoy ablyatsii i primeneniyu implantirov / [L. A. Bokeriya, A. S. Revishvili, S. P. Golitsin et al.]. – M.: Novaya redaktsiya, 2013. – 596 p.

QRS duration and QTc interval are predictors of risk for ventricular arrhythmias during cardiac resynchronization therapy / D.Prochnau, H. Kuehnert, H. R. Figulla, R. Surber. // Acta Cardiol. – 2011. – № 66. – P. 415–20.

Chiladakis J. A. Facilitating assessment of QT interval duration during ventricular pacing / J. A. Chiladakis, D. Alexopoulos. // Europace. – 2013. – № 20. – P. 907–914.

An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) / [A. Sagie, M. Larson, R. Goldberg et al.]. // Am. J. Cardiol. – 1992. – № 70. – P. 797–801.

Moss A. Long QT syndrome / A. Moss, J. Robinson. // Heart Dis. Stroke. – 1992. – № 1. – P. 309–314.

Singh J. P. Biventricular pacing: current trends and future strategies / J. P. Singh, D. Gras. // Eur Heart J. – 2012. – № 33. – P. 305–13.

Postoperative arrhythmias after cardiac surgery: incidence, risk factors, and therapeutic management / G.Peretto, A. Durante, L. R. Limite, D. Cianflone. // Cardiol Res Pract. – 2014. – № 1. – P. 615–627.

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease / [S. Goto, H. Ogawa, M. Takeuchi et al.]. // European Heart Journal. – 2010. – № 31. – P. 2601–2613.

Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study / [C. Iribarren, A. D. Round, J. A. Peng et al.]. // Pharmacoepidemiol Drug Saf. – 2013. – № 22. – P. 1222–32.

Clinical correlates and heritability of QT interval duration in blacks: the Jackson Heart Study / [E. L. Akylbekova, R. S. Crow, W. D. Johnson et al.]. // Circ Arrhythm Electrophysiol. – 2009. – № 2. – P. 427–32.

Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-Blockers / [S. G. Priori, C. Napolitano, P. J. Schwartz et al.]. // JAMA. – 2004. – № 292. – P. 1341–1344.

Do Beta-Blockers Affect Non-corrected QT Interval in Type 1 Long QT Syndrome? / [M. T. Bennett, L. J. Gula, G. J. Klein et al.]. // Circulation. – 2009. – № 120. – P. 653.

A Detailed Description and Assessment of Outcomes of Patients With Hospital Recorded QTc Prolongation / [Z. Laksman, B. Momciu, Y. W. Seong et al.]. // Am J Cardiol. – 2015. – № 15. – P. S0002–00051.

How to Cite
Brynza, M. S., & Yabluchansky, M. I. (1). QTc INTERVAL DURATION CLASS AND DRUG THERAPY OF PATIENCE IN A FIRST YEAR AFTER PACEMAKER IMPLANTATION. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (32), 5-11. Retrieved from https://periodicals.karazin.ua/medicine/article/view/7820
Section
Clinical research

Most read articles by the same author(s)